Comparison between conventional imaging methods and positron emission tomography in the treatment of Hodgkin's lymphoma;Srovnání konvenčních zobrazovacích metod a pozitronové emisní tomografie v léčbě Hodgkinova lymfomu

Casopis Lekaru Ceskych

Volumn 143, Issue 7, 2004, Pages 476-480

  Móciková, Heidi ^a   Markova J ^a   Belohlavek O ^b   Cap F ^a   Cermak F ^a   Feltl, D ^a   Kozak T ^a   Trněný, Marek ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Oddelení Nukleární Medicíny A PET Centrum Nemocnice Na Homolce   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Hodgkin's lymphoma; Positron emission tomography; Residual tumor

Indexed keywords

FLUORODEOXYGLUCOSE;

ADULT; ARTICLE; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FOLLOW UP; HISTOLOGY; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; POSITRON EMISSION TOMOGRAPHY; RELAPSE; RETROSPECTIVE STUDY; AGED; COMPARATIVE STUDY; DISEASE COURSE; FEMALE; LABORATORY DIAGNOSIS; MALE; MIDDLE AGED; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; DISEASE PROGRESSION; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY;

EID: 4043083475     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Weber, A. W., Avril, N., Schwaiger, M.: Relevance of positron emission tomography (PET) in oncology. Strahlenther. Onkol., 1999, 175, s. 356-373.
2. Buchmann, I., Reinhardt, M., Elsner, K. et al.: 2-(fluorine-18) fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer, 2001, 91, s. 889-899.
3. Jerusalem, G., Beguin, Y., Fassotte, M. F. et al.: Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Hematologica, 2001, 86, s. 266-273.
4. Menzel, C., Dobert, N., Mitrou, P. et al.: Positron emission tomography for the staging of Hodgkin's lymphoma. Increasing the body of evidence in favor of the method. Acta Oncol., 2002, 41, s. 430-436.
5. Munker, R., Glass, J., Zamani, R. et al.: Contribution of PET scanning to the initial staging of patients with Hodgkin's disease. The ASCO Annual Meeting May 31-June 3, 2003, Chicago, Illinois. Abstr. č. 2415.
6. th International Conference on Malignant Lymphoma, Suppl. 2. Abstr. č. 135.
7. Salloum, E., Schwab, Brandt, D. et al.: Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients. J. Clin. Oncol., 1997, 15, s. 518-527.
8. Dittmann, H., Sokler, M., Kollmannsberger, C. et al.: Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. Oncol. Rep., 2001, 8, s. 1393 až 1399.
9. Slabý, J., Trněný, M., Kupka, K. et al.: Využití funkčních zobrazovacích metod -galliové scintigrafie a pozitronové emisní tomografie -u nemocných s maligním lymfomem. Klin. Onkol., 2000, 6, s. 177-182.
10. Spaepen, K., Mortelmans, L.: Evaluation of treatment response in patients with lymphoma using /18F/FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease. Q. J. Nucl. Med., 2001, 45, s. 269-273.
11. Jerusalem, G., Beguin, Y., Fassotte, M. F. et al.: Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann. Onc., 2003, 14, s. 123-130.
12. Vinnicombe, S. J., Reznek, R. H.: Computerised tomography in the staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur. J. Nucl. Med. and Mol. Imaging., 2003, 30 (Suppl.1.), s. 42-55.
13. Hueltenschmidt, B., Sautter-Bihl, M. L., Lang, O. et al.: Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer, 2001, 91, s. 302-310.
14. Kostakoglu, L., Leonard, J. P., Kuji, I. et al.: Comparison of fluorine -18fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer, 2002, 94, s. 879-888.
15. Lang, O., Bihl, H., Hueltenschmidt, B. et al.: Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease. Strahlenther. Onkol., 2001, 177, s. 138-144.
16. Shah, N., Hoskin, P., McMillan, A. et al.: The impact of FDG positron emission tomography imaging on the management of lymphomas. Br. J. Radiol., 2000, 73, s. 482-487.
17. van Den Bossche, B., Lambert, B., de Winter, F. et al.: 18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients. Nucl. Med. Commun., 2002, 23, s. 1079-83.
18. Weihrauch, M. R., Re, D., Bischoff, S. et al.: Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging with Hodgkin's disease. Ann. Hematol., 2002, 81, s. 20-25.
19. Wirth, A., Seymour, J. F., Hicks, R. J. et al.: Fluorine-18fluorode- oxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am. J. Med., 2002, 112, s. 262-268.
20. Bangerter, M., Moog, F., Buchmann, I. et al.: Whole-body 2-/18 F/-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann. Oncol., 1998, 9, s. 1117-1122.
21. Carr, R., Barrington, S. F., O'Doherty, M. J. et al.: Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood, 1998, 91, s. 3340-3346.
22. Dobert, N., Menzel, C., Berner, U. et al.: Positron emission tomography in patients with Hodgkin's disease: correlation to histopathologic subtypes. Cancer Biother. Radiopharm., 2003, 18, s. 565-571.
23. Chiang, S. B., Rebenstock, A., Guan, L. et al.: Diffuse Bone Marrow involvement of Hodgkin's lymphoma mimics hematopoietic cytokine-mediated FDG uptake on FDG PET Imaging. Clin. Nucl. Med., 2003, 28, s. 674-676.
24. Cremerius, U., Fabry, U., Neuerburg, J. et al.: Prognostic significance of positron emission tomography using fluorine - 18 - fluorodeoxyglucose in patients treated for malignant lymphoma. Nuklearmedizin, 2001, 40, s. 23-30.
25. de Wit, M., Bohuslavizki, K. H., Buchert, R. et al.: 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann. Oncol., 2001, 12, s. 29-37.
26. Guay, C., Lepine, M., Verreault, J. et al.: Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J. Nucl. Med., 2003, 44, s. 1225-1231.
27. 18F-flurodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood, 2001, 98, s. 2930-2934.
28. Lavely, W. C., Delbeke, D., Greer, J. P. et al.: FDG PET in the follow -up management of patients with newly diagnosed Hodgkin and non Hodgkin lymphoma after first-line chemotherapy. Int. J. Radiat. Oncol. Biol. Phys., 2003, 57, s. 307-315.
29. Naumann, R., Vaic, A., Beuthien-Baumann, B. et al.: Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br. J. Haematol., 2001, 115, s. 793-800.